Conquest Research

Conquest Research would like to thank their entire team, but specifically recognize Dr. Patel, Emily, Natalie P., Sandy, Lisa, Brianne, Mark and Mackenzie for their efforts during the first FDA inspection in the history of Conquest. This was not a for-cause inspection; instead, it was the result of high-enrollment. Conquest enrolled ~20% of the study’s patient population. No 483s were issued and the inspector recommended NAI, or No Action Indicated. This is a testament to the fundamental goals of #ConquestResearch: to meet and exceed enrollment goals, protect #patientsafety above all else, and provide meaningful, high-quality data. #milestone #thankyou #gratitude 

Amylyx Pharmaceuticals’ investigational oral therapy AMX0035 reduces the levels of several #biomarkers associated with #AlzheimersDisease, according to results from the PEGASUS trial. AMX0035 is an oral combination of two small molecules: sodium phenylbutyrate and taurursodiol. AMX0035 significantly reduced the levels of core #Alzheimers CSF biomarkers, such as total tau protein and p-tau 181 compared with the placebo. Treatment also reduced levels of neurodegeneration biomarkers, specifically neurogranin and FABP3, and YKL-40, a biomarker linked to the rate of cognitive decline and brain volume loss.

The first patient with early #ParkinsonsDisease has been dosed in Ventyx Biosciences’ Phase 2a #clinicaltrial of VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3 protein. The trial is still recruiting patients at its single site in Connecticut. Top-line data are expected in 2025. VTX3232, an NLRP3 inhibitor, could potentially be used for neuroinflammatory and #neurodegenerative conditions including #Parkinsons, #AlzheimersDisease, and #multiplesclerosis.                                  

In a #partnership with Moderna, now expanded to two undisclosed #autoimmune targets, Carisma Therapeutics aim to simplify #celltherapy by bypassing the need to culture patient cells out of the body. The technique is called in vivo CAR-M therapy. In June, Carisma received a FDA Fast Track Designation for a CAR-M therapy treating HER2-overexpressing solid tumors. Under this #collaboration, Carisma and Moderna will leverage Carisma’s proprietary CAR-M technology and Moderna’s mRNA/LNP platform to develop novel in vivo macrophage engineering approaches in the nominated #autoimmunedisease targets.

Healthy living is healthy aging. For #HealthyAgingMonth, visit the HHS OASH Office of Disease Prevention and Health Promotion for #MoveYourWay resources. #PhysicalActivity can help #OlderAdults stay healthy and independent as you age. #GetActive and eating healthy are the key to getting strong, improving your balance while managing health concerns and preventing new ones. #HP2030 #seniors #ConquestResearch  

Abbott has launched a pivotal #clinicaltrial to see if its deep-brain stimulation approach can make headway against treatment-resistant #depression. The FDA previously granted Abbott a breakthrough designation to use the same technology to target the areas of the brain that help regulate mood. Abbott will begin enrolling about 100 people in a randomized, controlled trial—specifically those who were prescribed at least four different types of antidepressants but did not see significant benefits. Half will have their therapy turned on, while the other half will serve as a control group for one year. #deepbrainstimulation

About 51.6 million adult Americans experience #chronicpain. Each week during #PainAwarenessMonth, the U.S. Pain Foundation will release new Health Hack videos focusing on various aspects of living with #chronicpain. Let’s #SolvePainTogether. #clinicaltrials and more research data advances new treatments and better health outcomes. #PainCounts #painrelief #ChangingThePainEquation #painmanagement 

Eli Lilly and Company will expand its RNA pipeline by hedging $1B in biobucks on HAYA Therapeutics in search for preclinical #drugdiscovery in #obesity and related #metabolic conditions. Until now, Haya has used its drug discovery engine to target long noncoding RNAs (#lncRNAs) that are drivers for fibrotic diseases and other conditions associated with aging, including #cancer. Researchers have implicated a host of lncRNAs in the formation of fatty tissue. Haya’s platform enables the identification of lncRNA targets that are specific to different tissues, diseases and cells. Hitting the targets could reprogram cell states. #cardiometabolic #weightmanagement #RNAtherapy

Gain Therapeutics announces positive topline results from the #Phase1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for #ParkinsonsDisease with or without GBA1 mutation. The data demonstrated the drug’s presence in cerebrospinal fluid and peripheral target engagement. Its Phase 1b trial is anticipated in Q4’24 and the read out by mid-2025. Gain’s lead program in #Parkinsons has been awarded funding from The Michael J. Fox Foundation for Parkinson's Research and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.

#ConquestResearch wishes you a peaceful Labor Day filled with well-deserved rest and appreciation. We will resume normal business hours tomorrow. #HappyLaborDay2024 #HappyLaborDay